Pain, fatigue, depression and anxiety common in first year after multiple sclerosis diagnosis
21 July 2022
Pain, fatigue, depression and anxiety are common in established MS; this study monitored the symptoms during the first year after diagnosis of MS.
Updated NICE multiple sclerosis guideline contains some good news and some bad news
22 June 2022
There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.
Researching the genetics of MS
25 May 2022
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.
Is a ketogenic diet good for people with multiple sclerosis?
18 May 2022
Researchers assessed whether a ketogenic diet, low in carbohydrates and high in fats, is suitable for people with multiple sclerosis.
Mayzent (siponimod) use expanded in England for secondary progressive multiple sclerosis
3 May 2022
NHS England has agreed that Mayzent can be prescribed for people with active secondary progressive multiple sclerosis whose disability has increased for at least 6 months, unrelated to relapses, and while taking a disease modifying drug.
Can exercise therapy started soon after diagnosis affect the course of multiple sclerosis?
21 April 2022
Researchers have investigated whether the benefits of early treatment, which are well-established for disease modifying drugs, could also be applied to exercise therapy.
MS and Epstein-Barr virus in the news
19 April 2022
Multiple sclerosis and Epstein-Barr virus have been in the news with reports of new avenues for treatment. But how quickly might we see new treatments or cures?
Vumerity (diroximel fumarate) approved for relapsing remitting MS in England and Wales
13 April 2022
Vumerity (diroximel fumarate) has been approved by NICE for people with active relapsing remitting multiple sclerosis.
Covid-19 treatments for people with MS
30 March 2022
People with MS can get effective treatments if they get Covid-19. This article explains more about molnupiravir (Lagevrio) and sotrovimab (Xetrudy) and how to get them if you catch coronavirus.
Finding your way; how does MS affect navigation skills?
21 March 2022
In what they believe to be the first study of its kind, researchers investigated wayfinding skills - how we find our way between places - in people with MS.
How quickly do people with MS recover from Covid-19?
15 February 2022
This research, part of the UK MS Register Covid-19 study, investigated how well people with MS recover from mild to moderate Covid-19 and the factors that influence recovery.
Vumerity (diroximel fumarate) approved for relapsing remitting MS in Scotland
7 February 2022
Vumerity (diroximel fumarate) has been approved by the Scottish Medicines Consortium for people with relapsing remitting multiple sclerosis.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.